臺灣健保預檢規則實作指引
0.0.1 - CI Build

臺灣健保預檢規則實作指引, published by Example Publisher. This guide is not an authorized publication; it is the continuous build for version 0.0.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/TWNHIFHIR/cql/ and changes regularly. See the Directory of published versions

目錄

.. 0 目錄
... 1 應用說明
... 2 Libraries
... 3 Libraries下載
... 4 Artifacts Summary
.... 4.1 Abemaciclib給付規定-Abemaciclib Rule1
.... 4.2 CDK46給付規定-CDK46 Rule1
.... 4.3 乳癌代碼集-BCCodeConcept
.... 4.4 Everolimus給付規定-Everolimus Rule1
.... 4.5 Larotrectinib給付規定-Larotrectinib Rule1
.... 4.6 Olaparib給付規定-Olaparib Rule1
.... 4.7 Olaparib給付規定-Olaparib Rule2
.... 4.8 Pembrolizumab給付規定
.... 4.9 Pertuzumab給付規定-Pertuzumab Rule1
.... 4.10 Pertuzumab給付規定-Pertuzumab Rule2
.... 4.11 Pertuzumab與Trastuzumab_皮下(SC)給付規定-PertuzumabTrastuzumabSC Rule1
.... 4.12 Pertuzumab與Trastuzumab_皮下(SC)給付規定-PertuzumabTrastuzumabSC Rule2
.... 4.13 BCReusable
.... 4.14 Sacituzumab govitecan給付規定
.... 4.15 Talazoparib給付規定-Talazoparib Rule1
.... 4.16 Trastuzumab Deruxtecan給付規定-TrastuzumabDeruxtecan Rule1
.... 4.17 Trastuzumab Deruxtecan給付規定-TrastuzumabDeruxtecan Rule2
.... 4.18 Trastuzumab Emtansine給付規定-TrastuzumabEmtansine Rule1
.... 4.19 Trastuzumab Emtansine給付規定-TrastuzumabEmtansine Rule2
.... 4.20 Trastuzumab給付規定-Trastuzumab Rule1
.... 4.21 Trastuzumab給付規定-Trastuzumab Rule2
.... 4.22 Trastuzumab給付規定-Trastuzumab Rule3
.... 4.23 大腸直腸癌_Bevacizumab給付規定(轉移性大腸或直腸癌患者的第一線治療)
.... 4.24 大腸直腸癌_Bevacizumab給付規定(轉移性大腸或直腸癌病人的第二線治療)
.... 4.25 大腸直腸癌_Cetuximab給付規定1
.... 4.26 大腸直腸癌_Cetuximab給付規定2
.... 4.27 大腸直腸癌代碼集-CRCCodeConcept
.... 4.28 大腸直腸癌_Larotrectinib給付規定
.... 4.29 大腸直腸癌_Panitumumab給付規定
.... 4.30 大腸直腸癌_Pembrolizumab給付規定
.... 4.31 大腸直腸癌_Regorafenib給付規定
.... 4.32 規則共通模組-CRCReusable
.... 4.33 大腸直腸癌_Trifluridine/tipiracil給付規定
.... 4.34 Atezolizumab、Durvalumab給付規定
.... 4.35 肝癌代碼集
.... 4.36 Larotrectinib給付規定
.... 4.37 Lenvatinib給付規定
.... 4.38 Pemigatinib給付規定
.... 4.39 Ramucirumab給付規定
.... 4.40 Regorafenib給付規定
.... 4.41 肝癌規則共通模組
.... 4.42 Sorafenib給付規定
.... 4.43 Alectinib給付規定
.... 4.44 Atezolizumab、Durvalumab給付規定(小細胞肺癌)
.... 4.45 Bevacizumab給付規定
.... 4.46 Brigatinib給付規定
.... 4.47 Ceritinib給付規定
.... 4.48 肺癌代碼集
.... 4.49 Crizotinib給付規定
.... 4.50 Dabrafenib、Trametinib給付規定(非小細胞肺癌)
.... 4.51 Durvalumab給付規定(非小細胞肺鞏固(單用))
.... 4.52 Entrectinib給付規定
.... 4.53 Larotrectinib給付規定
.... 4.54 Lorlatinib給付規定
.... 4.55 Osimertinib給付規定(肺腺癌之第一線治療)
.... 4.56 Osimertinib給付規定(非小細胞肺癌第二線治療)
.... 4.57 Pembrolizumab、Nivolumab、Atezolizumab給付規定(鱗狀非小細胞肺癌第二線用藥(單用))
.... 4.58 Pembrolizumab、Nivolumab、Atezolizumab給付規定(非鱗狀非小細胞肺癌第三線用藥(單用) )
.... 4.59 Pembrolizumab、Atezolizumab給付規定(鱗狀、非鱗狀非小細胞肺癌第一線用藥(單用))
.... 4.60 Pembrolizumab、Atezolizumab給付規定(非鱗狀非小細胞肺癌第一線用藥(併用))
.... 4.61 Pembrolizumab給付規定(鱗狀非小細胞肺癌第一線用藥(併用))
.... 4.62 肺癌規則共通模組
.... 4.63 Tepotinib給付規定
.... 4.64 Abiraterone給付規定
.... 4.65 Apalutamide給付規定
.... 4.66 攝護腺癌代碼集
.... 4.67 Darolutamide給付規定-與docetaxel併用於治療高風險轉移性的去勢敏感性前列腺癌(mCSPC)
.... 4.68 Darolutamide給付規定-治療高風險非轉移性去勢抗性前列腺癌(high risk nmCRPC)的成年男性
.... 4.69 Enzalutamide給付規定-高風險非轉移性去勢抗性前列腺癌(high risk nmCRPC)
.... 4.70 Enzalutamide給付規定-高風險轉移性的去勢敏感性前列腺癌(mCSPC)
.... 4.71 Enzalutamide給付規定-藥物或手術去勢抗性的轉移性前列腺癌(mCRPC)-未化療
.... 4.72 Enzalutamide給付規定-藥物或手術去勢抗性的轉移性前列腺癌(mCRPC)-已化療
.... 4.73 Larotrectinib給付規定
.... 4.74 Olaparib給付規定
.... 4.75 Radium-223給付規定
.... 4.76 攝護腺癌規則共通模組
.... 4.77 FHIRHelpers